Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2006-05-10
2011-12-27
Bowman, Amy (Department: 1635)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C536S023100, C536S024500, C435S235100
Reexamination Certificate
active
08084433
ABSTRACT:
The invention provides antisense antiviral compounds and methods of their use and production in inhibition of growth of viruses of the Flaviviridae, Picomoviridae, Caliciviridae, Togaviridae, Arteriviridae, Coronaviridae, Astroviridae and Hepeviridae families in the treatment of a viral infection. The antisense antiviral compounds are substantially uncharged morpholino oligonucleotides having a sequence of 12-40 subunits, including at least 12 subunits having a targeting sequence that is complementary to a region associated with stem-loop secondary structure within the 5′-terminal end 40 bases of the positive-sense RNA strand of the virus.
REFERENCES:
patent: 5034506 (1991-07-01), Summerton et al.
patent: 5142047 (1992-08-01), Summerton et al.
patent: 5166315 (1992-11-01), Summerton et al.
patent: 5185444 (1993-02-01), Summerton et al.
patent: 5194428 (1993-03-01), Agrawal et al.
patent: 5217866 (1993-06-01), Summerton et al.
patent: 5495006 (1996-02-01), Climie et al.
patent: 5506337 (1996-04-01), Summerton et al.
patent: 5521063 (1996-05-01), Summerton et al.
patent: 5576302 (1996-11-01), Cook et al.
patent: 5580767 (1996-12-01), Cowsert et al.
patent: 5698685 (1997-12-01), Summerton et al.
patent: 5702891 (1997-12-01), Kolberg et al.
patent: 5734039 (1998-03-01), Calabretta et al.
patent: 5738985 (1998-04-01), Miles et al.
patent: 5801154 (1998-09-01), Baracchini et al.
patent: 5892023 (1999-04-01), Pirotzky et al.
patent: 5955318 (1999-09-01), Simons et al.
patent: 5989904 (1999-11-01), Das et al.
patent: 6060456 (2000-05-01), Arnold et al.
patent: 6133246 (2000-10-01), McKay et al.
patent: 6174868 (2001-01-01), Anderson et al.
patent: 6214555 (2001-04-01), Leushner et al.
patent: 6228579 (2001-05-01), Zyskind et al.
patent: 6239265 (2001-05-01), Cook
patent: 6258570 (2001-07-01), Glustein et al.
patent: 6306993 (2001-10-01), Rothbard et al.
patent: 6365351 (2002-04-01), Iversen
patent: 6365577 (2002-04-01), Iversen
patent: 6391542 (2002-05-01), Anderson et al.
patent: 6495663 (2002-12-01), Rothbard
patent: 6669951 (2003-12-01), Rothbard et al.
patent: 6677153 (2004-01-01), Iversen
patent: 6784291 (2004-08-01), Iversen et al.
patent: 6828105 (2004-12-01), Stein et al.
patent: 6841542 (2005-01-01), Bartelmez et al.
patent: 6841675 (2005-01-01), Schmidt et al.
patent: 6881825 (2005-04-01), Robbins et al.
patent: 7049431 (2006-05-01), Iversen et al.
patent: 7094765 (2006-08-01), Iversen et al.
patent: 7115374 (2006-10-01), Linnen et al.
patent: 7468418 (2008-12-01), Iversen et al.
patent: 7507196 (2009-03-01), Stein et al.
patent: 7524829 (2009-04-01), Stein et al.
patent: 7582615 (2009-09-01), Neuman et al.
patent: 2003/0166588 (2003-09-01), Iversen et al.
patent: 2003/0171311 (2003-09-01), Blatt et al.
patent: 2003/0171335 (2003-09-01), Stein et al.
patent: 2003/0224353 (2003-12-01), Stein et al.
patent: 2004/0072239 (2004-04-01), Renaud et al.
patent: 2004/0259108 (2004-12-01), Linnen et al.
patent: 2004/0265879 (2004-12-01), Iversen et al.
patent: 2005/0171044 (2005-08-01), Stein et al.
patent: 2005/0176661 (2005-08-01), Vaillant et al.
patent: 2006/0063150 (2006-03-01), Iversen et al.
patent: 2006/0148747 (2006-07-01), Stein et al.
patent: 2006/0149046 (2006-07-01), Arar
patent: 2006/0269911 (2006-11-01), Iversen et al.
patent: 2007/0004661 (2007-01-01), Stein et al.
patent: 2007/0066556 (2007-03-01), Stein et al.
patent: 2007/0129323 (2007-06-01), Stein et al.
patent: 2007/0265214 (2007-11-01), Stein et al.
patent: 2009/0012280 (2009-01-01), Stein et al.
patent: 2009/0082547 (2009-03-01), Iversen et al.
patent: 2009/0088562 (2009-04-01), Weller et al.
patent: 2009/0099066 (2009-04-01), Moulton et al.
patent: 2009/0186847 (2009-07-01), Stein et al.
patent: 2009/0186848 (2009-07-01), Stein et al.
patent: 2009/0186849 (2009-07-01), Stein et al.
patent: 2010/0063133 (2010-03-01), Neuman et al.
patent: WO 98/12312 (1998-03-01), None
patent: 98/33904 (1998-08-01), None
patent: 99/29350 (1999-06-01), None
patent: WO 01/49775 (2001-07-01), None
patent: WO 02/26968 (2002-04-01), None
patent: WO02/068637 (2002-09-01), None
patent: WO 02/068637 (2002-09-01), None
patent: 02/081495 (2002-10-01), None
patent: WO 03/033657 (2003-04-01), None
patent: WO03033657 (2003-04-01), None
patent: WO2005/007805 (2005-01-01), None
patent: WO2005/007805 (2005-01-01), None
patent: WO2005/013905 (2005-02-01), None
patent: WO2005/013905 (2005-02-01), None
patent: 2005/030800 (2005-04-01), None
patent: WO 2005/030800 (2005-04-01), None
patent: 2005/065268 (2005-07-01), None
patent: WO 2006/047683 (2006-04-01), None
patent: 2006/047683 (2006-05-01), None
patent: 2006/050414 (2006-05-01), None
patent: 2007/030576 (2007-03-01), None
patent: 2007/030691 (2007-03-01), None
patent: 2007/103529 (2007-09-01), None
Rothbard et al. (2002) J. Med. Chem. 45:3612-3618.
Moulton et al. (Sep. 7-11, 2003) Abstracts of Papers American Chemical Society National Meeting 226 (1-2): BIOL 75.
Agrawal et al. (1988) Proc. Natl. Acad. Sci. USA 85:7079-7083.
Kinney et al. (2005) “Inhibition of Dengue Virus Serotypes 1 to 4 in Vero Cell Cultures with Morpholino Oligomers” J. Virology 79:5116-5128.
Agrawal et al.Proc Natl Acad Sci U S A., 87(4):1401-5 (1990).
Bonham et al.,Nucleic Acids Res., 23(7):1197-203 (1995).
Boudvillain et al.,Biochemistry36(10):2925-31 (1997).
Branch, Andrea D.,TIBS, 23:45-50 (1998).
Clarke et al.,J. Infect. Diseases, 181:S309-S316 (2000).
Corey et al., Morpgolino Antisnese Oligonucleotides: Tools for Investigating Vertebrate Development, Genome Biology, 2(5):1015.1-1015.3 (2001).
Cross et al., “Solution structure of an RNA × DNA hybrid duplex containing a 3′-thioformacetal linker and an RNA A-tract.”Biochemistry, 36(14):4096-107 (1997).
Dagle et al., “Targeted elimination of zygotic messages in Xenopus laevis embryos by modified oligonucleotides possessing terminal cationic linkages”,Nucleic Acids Res., 28(10):2153-7 (2000).
Deas, T.S., et al.,Journal of Virology, 79(8):4599-4609, (2005).
Ding, D., et al.,Nucleic Acids Res., 24(2):354-60 (1996).
Egholm et al., “PNA hybridizes to complementary oligonucleotides obeying the Watson-Crick hydrogen-bonding rules.”Nature, 365(6446):566-8 (1993).
Felgner et al.,PNAS, 84(21):7413-7 (1987).
Gee et al.,Antisense Nucleic Acid Drug Dev8(2):103-11 (1998).
Genbank Accession No. AF304460.
Green et al.,J. Am. Coll. Surg., 191:93-105 (2000).
Jubin, R., et al.,Journal of Virology, 74(22):10430-10437, (2000).
Lopez De Quinto S. et al.,Virology, 255(2):324-336 (1999).
National Center for Biotechnology Information Report No. AF029248 from NCBI Genome Database (2000).
National Center for Biotechnology Information Report No. NC—002645 from NCBI Genome Database (2001).
National Center for Biotechnology Information Report No. AY274119 from NCBI Genome Database (2003).
Orr et al.,Current Opinion in Molecular Therapeuctics, Current Drugs, 2(3):325-331 (2000).
Partridge et al.,Antisense Nucleic Acid Drug Development, 6(3):169-175 (1996).
Raviprakash, K., et al.,Journal of Virology, 69(1):69-74, (1995).
Bailey, C. P., J. M. Dagle et al., “Cationic oligonucleotides can mediate specific inhibition of gene expression in Xenopus oocytes.”Nucleic Acids Res, 26(21): 4860-7 (1998).
Banerjee, R. and A. Dasgupta (2001). “Interaction of picornavirus 2C polypeptide with the viral negative-strand RNA.”J Gen Virol82 (Pt 11): 2621-7.
Banerjee, R. and A. Dasgupta (2001). “Specific interaction of hepatitis C virus protease/helicase NS3 with the 3′-terminal sequences of viral positive- and negative-strand RNA.” J Virol 75(4): 1708-21.
Banerjee, R., A. Echeverri, et al. (1997). “Poliovirus-encoded 2C polypeptide specifically binds to the 3′-terminal sequences of viral negative-strand RNA.” J Virol 71(12): 9570-8.
Banerjee, R., W. Tsai, et al. (2001). “Interaction of poliovirus-encoded 2C/2BC polypeptides with the 3′ terminus negative-strand cloverleaf requires an intact stem-loop b.”Virology, 280(1): 41-51.
Barawkar, D. A. and T.
Iversen Patrick L.
Stein David A.
Weller Dwight D.
AVI BioPharma Inc.
Bowman Amy
Seed IP Law Group PLLC
LandOfFree
Antisense antiviral compound and method for treating ssRNA... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antisense antiviral compound and method for treating ssRNA..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antisense antiviral compound and method for treating ssRNA... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4316051